Regeneron Pharmaceuticals $REGN
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS91
PHASE 3 / 2-338
RECRUITING52
READOUTS ≤12 MONTHS16
READOUT SLIPPED >6 MO47%
Delay Index: of 58 active trials registered more than a year ago, 27 have moved their primary completion (readout) date by more than 6 months since first registration (median +5.6 months). See all sponsors →
Open Regeneron Pharmaceuticals on the live radar map → 📅 $REGN readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| cemiplimab NCT03916627 |
P2 | Active, not recruiting | Non-small Cell Lung Cancer; Hepatocellular Carcinoma | 65 | 2025-03-31 (+35 mo) |
| NIMBLE NCT05070858 |
P3 | Active, not recruiting | Generalized Myasthenia Gravis | 288 | 2025-07-08 (+16 mo) |
| OPTIMA NCT05394116 |
P3 | Active, not recruiting | Fibrodysplasia Ossificans Progressiva | 63 | 2025-07-17 (+4 mo) |
| ELARA NCT06491914 |
P3 | Active, not recruiting | Neovascular Age-Related Macular Degeneration; Diabetic Macular Edema | 1126 | 2025-08-26 (-5 mo) |
| ENGAGE NCT05831176 |
P2 | Active, not recruiting | Eosinophilic Gastritis (EoG); Eosinophilic Duodenitis (EoD) | 22 | 2026-02-23 (-17 mo) |
| Fianlimab NCT05352672 |
P3 | Active, not recruiting | Melanoma | 1546 | 2026-03-12 (+17 mo) |
| ELM-2 NCT03888105 |
P2 | Active, not recruiting | B-cell Non-Hodgkin Lymphoma (B-NHL) | 515 | 2026-06-17 (+29 mo) |
| Fianlimab NCT06161441 |
P2 | Active, not recruiting | Resectable Non-small Cell Lung Cancer | 195 | 2026-08-24 (+11 mo) |
| cemiplimab NCT06190951 |
P2 | Active, not recruiting | Melanoma | 151 | 2026-11-02 (-50 mo) |
| COMBINE-EGFR-1 NCT04626635 |
P1/2 | Active, not recruiting | Advanced Solid Tumors | 548 | 2026-11-13 (+21 mo) |
| Olatorepatide NCT07431086 |
P2 | Active, not recruiting | Overweight or Obesity | 120 | 2026-11-13 |
| FERVENT-1 NCT06421636 |
P2 | Active, not recruiting | Non-Transfusion Dependent Beta-Thalassemia (NTDT) | 19 | 2026-12-03 (-14 mo) |
| ASCEND-QW NCT07477704 |
P2 | Active, not recruiting | Hypercholesterolemia | 438 | 2026-12-29 |
| Fianlimab NCT05608291 |
P3 | Active, not recruiting | Melanoma | 1564 | 2027-01-15 (-33 mo) |
| ROXI-ATLAS NCT07175428 |
P2 | Recruiting | Atrial Fibrillation (AF) | 1200 | 2027-02-09 (-2 mo) |
| ROXI-APEX NCT07015905 |
P3 | Recruiting | Venous Thromboembolism (VTE) | 2000 | 2027-02-20 |
| fianlimab NCT06246916 |
P3 | Recruiting | Melanoma | 560 | 2027-03-22 (+2 mo) |
| Ubamatamab NCT03564340 |
P1/2 | Recruiting | Recurrent Ovarian Cancer; Recurrent Fallopian Tube Cancer | 890 | 2027-05-10 (+61 mo) |
| ROXI-ASPEN NCT07213778 |
P3 | Recruiting | Symptomatic Venous Thromboembolism (VTE) | 2000 | 2027-05-17 (-2 mo) |
| Mibavademab NCT07220772 |
P3 | Recruiting | Monogenic Obesity | 4 | 2027-06-18 (+2 mo) |
| REGN5093 NCT04077099 |
P1/2 | Active, not recruiting | NSCLC | 95 | 2027-07-06 (+42 mo) |
| ALN-PNP NCT05648214 |
P1/2 | Recruiting | Healthy Volunteers; Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | 172 | 2027-08-10 (+44 mo) |
| ALN-CIDEB NCT06836609 |
P1/2 | Active, not recruiting | Metabolic Dysfunction-Associated Steatotic Liver Disease; Metabolic Dysfunction-Associated Steatohepatitis | 118 | 2027-08-17 (+6 mo) |
| fianlimab NCT05785767 |
P2/3 | Active, not recruiting | Advanced Non-Small Cell Lung Cancer | 149 | 2027-09-28 (-14 mo) |
| REGN5678 NCT03972657 |
P1/2 | Recruiting | Metastatic Castration-Resistant Prostate Cancer (mCRPC); Clear Cell Renal Cell Carcinoma (ccRCC) | 345 | 2027-11-15 (+40 mo) |
| Vonsetamig NCT05092347 |
P1/2 | Active, not recruiting | Chronic Kidney Disease (CKD) | 43 | 2027-11-22 (+32 mo) |
| Cemiplimab NCT03969004 |
P3 | Active, not recruiting | Cutaneous Squamous Cell Carcinoma | 415 | 2028-01-07 (+31 mo) |
| Olatorepatide NCT07685808 |
P2 | Recruiting | Overweight or Obesity | 360 | 2028-01-21 |
| BNT116 NCT05557591 |
P2 | Active, not recruiting | Advanced Non-Small Cell Lung Cancer | 51 | 2028-01-26 (+9 mo) |
| KYRIAD NCT07235917 |
P2 | Recruiting | Functional Hypothalamic Amenorrhea; FHA | 34 | 2028-01-28 |
| ILLUMINATE NCT07318597 |
P2 | Recruiting | Pulmonary Arterial Hypertension (PAH) | 99 | 2028-02-27 |
| OLYMPIA-1 NCT06091254 |
P3 | Recruiting | Follicular Lymphoma (FL) | 822 | 2028-02-29 (-12 mo) |
| OLYMPIA-3 NCT06091865 |
P3 | Recruiting | Diffuse Large B-cell Lymphoma (DLBCL) | 904 | 2028-03-30 (-4 mo) |
| NASHGEN-2 NCT05519475 |
P2 | Active, not recruiting | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | 120 | 2028-04-27 (+20 mo) |
| LAGO NCT07220785 |
P3 | Recruiting | Generalized Lipodystrophy | 28 | 2028-05-19 |
| OLYMPIA-4 NCT06230224 |
P3 | Active, not recruiting | B-Cell Non-Hodgkin Lymphoma (B-NHL) | 216 | 2028-05-29 (+11 mo) |
| FDC fianlimab+cemiplimab NCT06769698 |
P2 | Recruiting | Head and Neck Squamous Cell Carcinoma (HNSCC) | 120 | 2028-06-04 (+13 mo) |
| EoE-TOTs NCT07112378 |
P3 | Recruiting | Eosinophilic Esophagitis (EoE) | 20 | 2028-06-19 (-2 mo) |
| Ubamatamab NCT06787612 |
P2 | Recruiting | Ovarian Cancer; Fallopian Tube Cancer | 397 | 2028-06-30 (+2 mo) |
| SIENNA NCT06541704 |
P3 | Recruiting | Age-related Macular Degeneration (AMD); Geographic Atrophy (GA) | 975 | 2028-07-31 (+13 mo) |
| LINKER-AL2 NCT06292780 |
P1/2 | Recruiting | Relapsed/Refractory Systemic Light Chain Amyloidosis | 220 | 2028-08-20 |
| ACCESS-EXT NCT05744921 |
P3 | Recruiting | Paroxysmal Nocturnal Hemoglobinuria | 202 | 2028-10-10 (+6 mo) |
| ANCHOR-POC NCT07271186 |
P2 | Recruiting | Diabetic Kidney Disease (DKD) | 195 | 2028-10-13 |
| REGN5668 NCT04590326 |
P1/2 | Recruiting | Ovarian Cancer; Fallopian Tube Cancer | 612 | 2028-11-08 (+32 mo) |
| Olatorepatide NCT07830329 |
P2 | Recruiting | Hidradenitis Suppurativa | 300 | 2028-11-24 |
| RISE-1 NCT07896265 |
P3 | Not yet recruiting | Overweight or Obesity Without Diabetes | 3000 | 2028-12-19 |
| ALN-CIDEB NCT07631637 |
P2 | Recruiting | Metabolic Dysfunction-Associated Steatohepatitis; MASH | 360 | 2029-01-29 |
| CHORD NCT05788536 |
P1/2 | Recruiting | Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF) | 36 | 2029-02-26 (-13 mo) |
| ALN-CIDEB NCT07854782 |
P3 | Recruiting | Metabolic Dysfunction-Associated Steatotic Liver Disease; MASLD | 1500 | 2029-03-03 |
| ROXI-INCLINE NCT07430956 |
P3 | Recruiting | Atrial Fibrillation (AF) | 2628 | 2029-03-28 |
| ALN-CIDEB NCT07933328 |
P2 | Not yet recruiting | Alcohol-Associated Liver Disease; ALD | 120 | 2029-05-07 |
| LINKER-MM5 NCT07222761 |
P3 | Recruiting | Relapsed and/or Refractory Multiple Myeloma (RRMM) | 915 | 2029-05-21 |
| REGN-2Cat NCT07675811 |
P3 | Recruiting | Allergic Conjunctivitis | 570 | 2029-05-31 |
| ROXI-PEAK NCT07697599 |
P3 | Recruiting | Venous Thromboembolism (VTE) | 1908 | 2029-06-25 |
| OLYMPIA-2 NCT06097364 |
P3 | Active, not recruiting | Follicular Lymphoma (FL) | 733 | 2029-07-29 (-5 mo) |
| ROXI-PALISADE NCT07318610 |
P3 | Recruiting | Peripheral Artery Disease (PAD) | 7050 | 2029-08-18 |
| ROXI-EVEREST NCT07626411 |
P3 | Recruiting | Atrial Fibrillation (AF) | 15364 | 2029-09-11 |
| BAHAMA NCT07675824 |
P1/2 | Recruiting | Primary Open Angle Glaucoma (POAG); Ocular Hypertension (OHT) | 271 | 2029-09-14 |
| REGN9220 NCT07887750 |
P1/2 | Not yet recruiting | Diffuse Large B-Cell Lymphoma (DLBCL) | 36 | 2029-11-01 |
| ALN-CFB NCT07187401 |
P1/2 | Recruiting | Paroxysmal Nocturnal Hemoglobinuria (PNH); Persistent Anemia | 24 | 2029-11-29 (+2 mo) |
| Cemiplimab NCT06465329 |
P2 | Active, not recruiting | Non Small Cell Lung Cancer; NSCLC | 184 | 2029-12-04 (+29 mo) |
| ROXI-DAISEN NCT07876492 |
P3 | Not yet recruiting | Secondary Stroke | 6106 | 2029-12-15 |
| fianlimab NCT05800015 |
P2/3 | Active, not recruiting | Non-small Cell Lung Cancer | 160 | 2030-01-16 (-16 mo) |
| Pozelimab NCT07154745 |
P3 | Recruiting | Paroxysmal Nocturnal Hemoglobinuria | 35 | 2030-01-18 (-12 mo) |
| ROXI-CAT-I NCT07410117 |
P3 | Recruiting | Cancer-Associated Thrombosis (CAT) | 1120 | 2030-01-23 |
| BrILliance NCT06413680 |
P1/2 | Recruiting | Melanoma; Clear-Cell Renal-Cell Carcinoma (ccRCC) | 240 | 2030-02-03 (-2 mo) |
| ALN-PNP NCT07527910 |
P2 | Recruiting | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | 204 | 2030-03-15 |
| REGN4336 NCT05125016 |
P1/2 | Recruiting | Metastatic Castration-resistant Prostate Cancer | 228 | 2030-03-28 (+44 mo) |
| Cemiplimab NCT06585410 |
P3 | Recruiting | Cutaneous Squamous Cell Carcinoma (CSCC) | 369 | 2030-05-03 (+11 mo) |
| Ubamatamab NCT07154290 |
P2 | Recruiting | Non Small Cell Lung Cancer; Advanced Non Small Cell Lung Cancer | 300 | 2030-06-10 |
| OPTIMA-2 NCT07559513 |
P3 | Not yet recruiting | Fibrodysplasia Ossificans Progressiva; FOP | 18 | 2030-07-08 |
| Fianlimab+cemiplimab NCT06848088 |
P2 | Active, not recruiting | Melanoma | 28 | 2030-10-09 (+12 mo) |
| REGN15505 NCT07594106 |
P1/2 | Recruiting | Metastatic Castration-Resistant Prostate Cancer (mCRPC); Clear Cell Renal Cell Carcinoma (ccRCC) | 265 | 2030-10-27 |
| Cemiplimab NCT07808515 |
P2 | Not yet recruiting | Locally Advanced Basal Cell Carcinoma | 135 | 2030-11-13 |
| ALN-6457 NCT07832370 |
P1/2 | Not yet recruiting | Prion Disease | 60 | 2031-02-27 |
| REGN13089-M404-M2980 NCT07863024 |
P1/2 | Not yet recruiting | Advanced Solid Tumors | 320 | 2031-03-10 |
| OLYMPIA-5 NCT06149286 |
P3 | Recruiting | Relapsed/Refractory Follicular Lymphoma; Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) | 580 | 2031-04-30 (+23 mo) |
| ROXI-CAT-II NCT07493304 |
P3 | Recruiting | Venous Thromboembolism (VTE) | 1600 | 2031-07-18 |
| REGN21353 NCT07850921 |
P1/2 | Not yet recruiting | Metastatic Castration-Resistant Prostate Cancer; mCRPC | 192 | 2031-07-28 |
| GOALS NCT06351592 |
P1/2 | Recruiting | Amyotrophic Lateral Sclerosis (ALS); Mutation in the Superoxide Dismutase-1 (SOD1) Gene | 54 | 2032-03-21 (+35 mo) |
| LINKER-MGUS1 NCT06140524 |
P2 | Recruiting | Monoclonal Gammopathy of Undetermined Significance (MGUS); Smoldering Multiple Myeloma (SMM) | 116 | 2032-05-18 (+3 mo) |
| Cemiplimab NCT07567469 |
P1/2 | Not yet recruiting | High-Grade Glioma (HGG); Posterior Fossa-A Ependymoma | 120 | 2032-08-27 |
| Linvoseltamab NCT05955508 |
P2 | Active, not recruiting | Smoldering Multiple Myeloma (SMM) | 40 | 2033-01-25 (+9 mo) |
| LINKER-MM1 NCT03761108 |
P1/2 | Recruiting | Multiple Myeloma | 387 | 2033-03-30 |
| LINKER-MM3 NCT05730036 |
P3 | Recruiting | Relapsed Refractory Multiple Myeloma (RRMM) | 410 | 2033-04-19 (+6 mo) |
| LINKER-SMM2 NCT07393282 |
P3 | Recruiting | High Risk Smoldering Multiple Myeloma (HR-SMM) | 270 | 2033-07-27 |
| Linvoseltamab NCT07455851 |
P1/2 | Recruiting | Relapsed Refractory Multiple Myeloma (RRMM) | 150 | 2033-09-30 |
| COSTIMM NCT06669247 |
P1/2 | Recruiting | Relapsed/Refractory Multiple Myeloma | 186 | 2033-11-11 (+1 mo) |
| BEYOND-9 NCT06379789 |
P1/2 | Recruiting | Hemophilia B | 130 | 2034-08-14 (+25 mo) |
| LINKER-AL1 NCT07901725 |
P3 | Not yet recruiting | Newly Diagnosed Amyloidosis; Amyloidosis Stage I-IIIA | 382 | 2035-07-25 |
| LINKER-MM4 NCT05828511 |
P1/2 | Active, not recruiting | Multiple Myeloma | 148 | 2035-11-02 (+4 mo) |